The group discusses how the addition of belzutifan to adjuvant pembrolizumab may represent an important next step in high-risk RCC, particularly given the persistent recurrence risk seen even after standard adjuvant immunotherapy. They highlight that the disease-free survival benefit is encouraging, especially because the curves remained separated over time, though overall survival remains immature and toxicity must be weighed carefully in a curative-intent setting. The conversation also raises important questions about which risk groups benefit most, whether current risk models are still adequate, and how biology may ultimately help refine who should receive treatment intensification.
Contributors:
Dr. Pedro Barata is a medical oncologist in Cleveland, Ohio and is affiliated with University Hospitals Cleveland Medical Center.
Dr. Bradley McGregor is a medical oncologist at Dana-Farber in Boston.
Dr. Neil Shah is a medical oncologist at Memorial Sloan Kettering Cancer Center.
Dr. Michael Serzan is a medical oncologist at Dana-Farber in Boston.
